NO951608L - Anvendelse av BHAP-forbindelser i kombinasjon med andre ikke-nukleoside reverstranskriptaseinhibitorer for behandling av HIV-infeksjon - Google Patents

Anvendelse av BHAP-forbindelser i kombinasjon med andre ikke-nukleoside reverstranskriptaseinhibitorer for behandling av HIV-infeksjon

Info

Publication number
NO951608L
NO951608L NO951608A NO951608A NO951608L NO 951608 L NO951608 L NO 951608L NO 951608 A NO951608 A NO 951608A NO 951608 A NO951608 A NO 951608A NO 951608 L NO951608 L NO 951608L
Authority
NO
Norway
Prior art keywords
hiv
treatment
bhap
compounds
combination
Prior art date
Application number
NO951608A
Other languages
English (en)
Other versions
NO951608D0 (no
Inventor
William Gary Tarpley
Thomas Jerome Dueweke
Donald Herman M D Batts
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of NO951608D0 publication Critical patent/NO951608D0/no
Publication of NO951608L publication Critical patent/NO951608L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Foreliggende oppfinnelse er metoder for behandling av et HlV-posi- tivt menneske som omfatter (l) admini- strering til det HIV-positive individ av en sensibiliserende effektiv mengde av en sensibiliserende HIV-1-inhibitor inntil forøkt sensibilitet overfor et ikke-nukleosid HlV-behandlingslege- middel utvikles, (2) administrering til det HIV-positive individ av en effektiv mengde av et ikke-nukleosid HlV-behand- lingslegemiddel. En alternativ metode er en metode for behandling av et HIV- positivt menneske som omfatter admini- strering til det HIV-positive individ av en sensibiliserende effektiv mengde av en eller flere sensibiliserende HIV- 1-inhibitorer samtidig med en effektiv mengde av et ikke-nukleosid HlV-behand- lingslegemiddel.
NO951608A 1992-10-28 1995-04-27 Anvendelse av BHAP-forbindelser i kombinasjon med andre ikke-nukleoside reverstranskriptaseinhibitorer for behandling av HIV-infeksjon NO951608L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US96763992A 1992-10-28 1992-10-28
US1711993A 1993-02-12 1993-02-12
PCT/US1993/008354 WO1994009781A1 (en) 1992-10-28 1993-09-10 Use of bhap compounds in combination with other non-nucleoside reverse transcriptase inhibitors for the treatment of hiv infection

Publications (2)

Publication Number Publication Date
NO951608D0 NO951608D0 (no) 1995-04-27
NO951608L true NO951608L (no) 1995-06-28

Family

ID=26689480

Family Applications (1)

Application Number Title Priority Date Filing Date
NO951608A NO951608L (no) 1992-10-28 1995-04-27 Anvendelse av BHAP-forbindelser i kombinasjon med andre ikke-nukleoside reverstranskriptaseinhibitorer for behandling av HIV-infeksjon

Country Status (12)

Country Link
EP (1) EP0666744A1 (no)
JP (1) JPH08502745A (no)
KR (1) KR950703958A (no)
AU (1) AU4848293A (no)
CA (1) CA2145545A1 (no)
CZ (1) CZ69695A3 (no)
FI (1) FI952018A0 (no)
HU (1) HUT72050A (no)
MX (1) MX9306031A (no)
NO (1) NO951608L (no)
PL (1) PL308551A1 (no)
WO (1) WO1994009781A1 (no)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW406075B (en) * 1994-12-13 2000-09-21 Upjohn Co Alkyl substituted piperidinyl and piperazinyl anti-AIDS compounds
JP4544820B2 (ja) 2001-03-09 2010-09-15 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド 複素環化合物
AU2003265886A1 (en) 2002-09-06 2004-03-29 Janssen Pharmaceutica N.V. (1H-Benzoimidazol-2-yl)-(piperazinyl)-methanone derivatives and related compounds as histamine H4-receptor antagonists for the treatment of inflammatory and allergic disorders
US8541407B2 (en) 2010-03-31 2013-09-24 Arqule, Inc. Substituted benzo-pyrido-triazolo-diazepine compounds
US8569331B2 (en) 2010-11-01 2013-10-29 Arqule, Inc. Substituted benzo[f]lmidazo[1,2-d]pyrido[2,3-b][1,4]diazepine compounds

Also Published As

Publication number Publication date
NO951608D0 (no) 1995-04-27
FI952018A (fi) 1995-04-27
FI952018A0 (fi) 1995-04-27
PL308551A1 (en) 1995-08-21
JPH08502745A (ja) 1996-03-26
CA2145545A1 (en) 1994-05-11
WO1994009781A1 (en) 1994-05-11
EP0666744A1 (en) 1995-08-16
CZ69695A3 (en) 1995-12-13
AU4848293A (en) 1994-05-24
HUT72050A (en) 1996-03-28
HU9501218D0 (en) 1995-06-28
KR950703958A (ko) 1995-11-17
MX9306031A (es) 1994-04-29

Similar Documents

Publication Publication Date Title
ATE168268T1 (de) Behandlung von menschlichen retrovirus- infektionen mit 2',3'-dideoxyinosin
ATE238998T1 (de) Substituierte benzimidazole als nicht-nucleoside reverse transcriptase inhibitore
BR9608265A (pt) Compostos de alquiléter e pirimidina-tioalquila alfa-substituídos
DK524788A (da) Anvendelse af morphin-antagonister til fremstilling af laegemidler med immunomodulerende og antiviral effekt, isaer til behandling af erhvervede immundefekt-tilstande
DE69019533T2 (de) Behandlung von hiv-infizierungen und nützliche verbindungen dafür.
BR9709838A (pt) Regime de administração que fornece um perfil de plasma no sangue de um inibidor de h+,k+-atpase composição farmacêutica oral uso da mesma e de inibidor h+,k+-atpase e processos para melhorar a inibição de secreção de ácido gástrico e o efeito terapêutico no tratamento de perturbações gastrintestinais e para receber um perfil estendido de plasma de um inibidor de h+,k+-atpase
DK261490D0 (da) New pharmaceutical compound
DK0763017T3 (da) N-(3-amino-2-hydroxybutyl)sulfonamidderivater som HIV-proteaseinhibitorer
KR910700045A (ko) Hiv 감염 관련 질병의 치료
DE69414708D1 (de) Verbindungen und methoden zur inhibition von hiv und verwandten viren
NO951608L (no) Anvendelse av BHAP-forbindelser i kombinasjon med andre ikke-nukleoside reverstranskriptaseinhibitorer for behandling av HIV-infeksjon
Kasbekar Studies of resting isolated frog gastric mucosa.
BR0317095A (pt) Uso de uma combinação contendo um inibidor da transcriptase reversa sem ser de nucleosìdeo (nnrti) com um inibidor citocromo p450, tal como inibidores da protease
ATE245444T1 (de) Pharmazeutische zusammensetzung, enthaltend peg- asparaginase, für die behandlung von hiv infektionen
EA199700150A1 (ru) КОМБИНИРОВАННОЕ ЛЕЧЕНИЕ ПО ПОВОДУ ВИЧ ИНФЕКЦИИ С ИСПОЛЬЗОВАНИЕМ ИНГИБИТОРА ПРОТЕАЗЫ ВИЧ ИНДИНАВИРА И ИНГИБИТОРА ОБРАТНОЙ ТРАНСКРИПТАЗЫ 3TC, НЕОБЯЗАТЕЛЬНО СОВМЕСТНО С AZT, ddI ИЛИ ddC
DK0859613T3 (da) Anvendelse af flupirtin til forebyggelse og behandling af sygdomme, som er forbundet med beskadigelse af det hæmopoietiske cellesystem
KR950702838A (ko) 인터루킨-4(IL-4)를 사용한 사람 면역결핍 바이러스(HIV) 복제의 억제방법(Method for inhibiting HIV replication using IL-4)
WO1997026880A3 (en) Use of a combination of delavirdine and one or more protease inhibitors in hiv-1 infected patients
NO965591L (no) Kombinasjonsbehandling av HIV-infeksjon
SE7701441L (sv) Nytt piperazinyluracilsalt
DK1143976T3 (da) Beta-D-2', 3'-didehydro-2', 3'-dideoxy-5-fluorcytidin til anvendelse i behandlingen af HIV-infektioner
RU94032792A (ru) Применение 5нтiа - антагонистов для прекращения использования табака
DK0910405T3 (da) Vaccine, som indeholder caprint arthritis-encephalitis-virus, og anvendelse til immunbeskyttelse imod HIV-1-infektion
UA31078A (uk) Інгібітор вірусу імунодефіциту людини ( даримід )
NO931338L (no) Forbindelser og fremgangsmaater for inhibering av hiv og beslektede virus